Photo: Andrew Harnik / Getty Images News / Getty Images
The Supreme Court has temporarily maintained access to the abortion pill mifepristone by mail, following a decision by Justice Samuel Alito to extend an emergency order until Thursday (May 14) at 5 p.m. Eastern. This decision pauses a ruling from the 5th U.S. Circuit Court of Appeals that mandated in-person visits for obtaining the drug.
Mifepristone, used in approximately 60% of abortions in the U.S., has become more prevalent since the Supreme Court overturned Roe v. Wade. The 5th Circuit's decision, which sparked regulatory confusion, was challenged by Danco Laboratories and GenBioPro, manufacturers of the drug. They argue that the ruling disrupts time-sensitive medical decisions, as reported by SCOTUSblog.
The appeals court's ruling had already caused chaos, impacting patients who rely on telehealth and pharmacy access for mifepristone. Health Affairs noted that the ruling could prevent patients from receiving timely care.
In response, Danco and GenBioPro sought emergency relief from the Supreme Court to maintain the status quo while the case proceeds. The companies argue that the 5th Circuit's decision could cut off access to mifepristone nationwide, affecting states where abortion remains legal.
The legal battle over mifepristone's distribution is part of a broader conflict over abortion rights in the U.S. Since the Supreme Court's 2022 decision to overturn Roe v. Wade, mail-order prescriptions have become a crucial method for obtaining abortions, especially in states with restrictive laws.
The Supreme Court's decision to extend the emergency order provides temporary relief, but the future of mifepristone's accessibility remains uncertain as the legal challenges continue.